Accentia Biopharma to report positive data on three therapeutics in 1H08
December 28, 2007: 06:11 PM EST
SAN FRANCISCO, Dec. 28, 2007 (Thomson Financial delivered by Newstex) -- Accentia Biopharmaceuticals Inc. (NASDAQ:APBI) late Friday said it plans to report positive Phase III clinical results on three of its therapeutics in the first half of 2008, which is expected to accelerate U.S. and European regulatory approvals.
The three are
BiovaxID, a personalized anti-cancer vaccine initially targeting non-Hodgkin's lymphoma;
Revimmune, a treatment for up to 80 autoimmune diseases, with an initial indication of multiple sclerosis;
and SinuNase, a treatment for chronic sinusitis.
The Tampa, Fla.-based company also said that Todd Thomason has resigned from the board, in connection with his decision to take a job with company in the health-care industry.
In addition, Accentia said it has filed its annual report for the fiscal year ended Sept. 30, 2007, with the Securities and Exchange Commission.
The company's stock closed the regular session up 23 cents, or almost 8%, at $3.14.
Katherine Hunt
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
Newstex ID: AFX-0013-21940675
money.cnn.com |
